1644670-37-0 Iptacopan

Pwopriyete

Aparans koupe-blan gri solid
Pwen bouyi: 599.1 ± 5 0. 0 degre
Dansite 1.25 ± 0. 1 g/cm3
Depo tanperati. Magazen nan -20 degre
solubility dmso: 5 0. 0 (max conc. mg/ml); 118.34 (max conc. mm)
pka4. 0 7 ± 0.10

 

Aplikasyon:

Se depozisyon konpleman souvan wè nan rapò byopsi ren nan pasyan ki gen imunoglobulin A (IgA) nefropati, se konsa kèk entelektyèl espekile ke anpeche konpleman ka trete kèk pasyan nefropati IgA. Iptacopan (LNP023) se yon faktè B inibitè ki gen konpleman efè inhibition. Nan etid klinik anvan yo, konpare ak glikokortikoyid yo, enpak li sou sistèm iminitè a ak sistèm andokrin yo te relativman ti, ak risk pou yo evènman grav negatif te relativman ba. Li kapab itilize pou trete nefropati IgA.

 

Sinonim:

iptakopan

1644670-37-0

Lnp023

LNP -023

NVP-LNP023

Nvp-lnp 023- nx

4- [(2s, 4s) -4- ethoxy -1- [(5- methoxy -7- Methyl -1 h-indol -4- yl) methyl] Piperid {

Asid benzoik, 4- [(2s, 4s) -4- ethoxy -1- [(5- methoxy -7- methyl {7}

Fabhalta

LNP 023

Asid benzoik, 4- ((2s, 4s) -4- ethoxy -1- ((5- methoxy -7- methyl -1 h-indol -4- y) {

4- ((2s, 4s) -4- ethoxy -1- ((5- methoxy -7- Methyl -1 h-indol -4- yl) methyl) Piperid {

4- [(2 ~ {s}, 4 ~ {s}) -4- ethoxy -1- [(5- metoksi -7- te rankontre hyl -1 ~ {h} -indol -4- yl) methyl] piperidin -2- yl] benzoic asid

iptakopanum

4- {(2s, 4s) -4- ethoxy -1- [(5- methoxy -7- Methyl -1 H-inol {{9} oul) Piper] Piper] {

Faktè B inibitè LNP023

GTPL10710

Lnp023

 

 

Baj popilè: 1644670-37-0 iptacopan, Lachin 1644670-37-0 manifaktirè iptakopan, founisè